<DOC>
	<DOCNO>NCT01467648</DOCNO>
	<brief_summary>This prospective randomized study ass pharmacodynamics ( &gt; MIC ) 0.5 g every 8 h doripenem patient VAP follow administration 4 h infusion 1 h infusion . Clinical laboratory data Age , Sex , Body weight , Electrolyte , Vital sign , APACHE II score , BUN , Cr , Blood culture collect . Twelve patient enrol study . After completion doripenem therapy 3 day study , patient receive sensitive antibiotic eradicate bacterial infection . Doripenem pharmacokinetic study carry doripenem therapy . Blood sample ( approximately 2 ml ) group `` 0.5 g doripenem 4 h infusion every 8 h regimen '' obtain direct venepuncture follow time : 0 , 0.5 , 1 , 2 , 3 , 4 , 4.5 , 5 , 6 , 7 8 h 7th dose doripenem . Blood sample ( approximately 2 ml ) group `` 0.5 g doripenem 1 h infusion every 8 h regimen '' obtain direct venepuncture follow time : 1 , 1.5 , 2 , 4 , 5 , 6 , 7 8 h 7th dose doripenem . The doripenem assay method Ikeda K et al . ( J Chromatogr B , 2008 ) perform . Concentration doripenem plasma simulate Monte Carlo technique ( Computer model ) get PK/PD index ( 40 % T &gt; MIC ) report % PTA ( Probability Target Attainment ) % CFR ( Cumulative Faction Response )</brief_summary>
	<brief_title>The Pharmacodynamics Doripenem Between 4-hour 1-hour Infusion Patients With Ventilator-associated Pneumonia</brief_title>
	<detailed_description>Introduction : The treatment resistant pathogen become difficult , novel antimicrobial agent currently development activity highly resistant Gram negative bacteria . Doripenem carbapenem antibacterial agent broad spectrum activity Gram-negative Gram-positive bacteria . This agent often use last line therapy highly resistant Gram negative bacillus nosocomial pathogen . In common beta-lactam , main pharmacokinetic/pharmacodynamic ( PK/PD ) index correlate therapeutic efficacy time concentration tissue serum MIC ( &gt; MIC ) . However , tropical country stability carbapenem antibiotic important consideration consider continuous infusion . Therefore , prolonged infusion may useful route administration maximize bactericidal activity . In addition , pharmacokinetic change find several antimicrobial agent critically ill patient , include ventilator-associated pneumonia . However , data reveal PK/PD index doripenem critically ill patient . Objectives : To assess pharmacodynamics ( &gt; MIC ) 0.5 g every 8 h doripenem patient VAP follow administration 4 h infusion 1 h infusion . Clinical laboratory data : Age , Sex , Body weight , Electrolyte , Vital sign , APACHE II score , BUN , Cr , Blood culture Drug preparation administration : Doripenem reconstitute saline solution accord manufacturer 's guideline administer patient 2 regimen : 1.0.5 g 100 ml normal saline solution administer via infusion pump constant flow rate 4 h every 8 h. 2.0.5 g 100 ml normal saline solution administer via infusion pump constant flow rate 1 h every 8 h. Study design : The study plan prospective randomized patient VAP . Each patient receive doripenem 2 regimen room temperature ( 37°C ) consecutively : ( ) infusion 0.5 g doripenem 4 h via infusion pump constant flow rate every 8 h ; ( ii ) infusion 0.5 g doripenem 1 h via infusion pump constant flow rate every 8 h. Twelve patient enrol study . After completion doripenem therapy 3 day study , patient receive sensitive antibiotic eradicate bacterial infection . Sample collection : Doripenem pharmacokinetic study carry doripenem therapy . Blood sample ( approximately 2 ml ) group `` 0.5 g doripenem 4 h infusion every 8 h regimen '' obtain direct venepuncture follow time : 0 , 0.5 , 1 , 2 , 3 , 4 , 4.5 , 5 , 6 , 7 8 h 7th dose doripenem . Blood sample ( approximately 2 ml ) group `` 0.5 g doripenem 1 h infusion every 8 h regimen '' obtain direct venepuncture follow time : 1 , 1.5 , 2 , 4 , 5 , 6 , 7 8 h 7th dose doripenem . All blood sample allow clot cebtrifuged 2,000g . The serum obtain store at-80°C analysis . Doripenem assay : The doripenem assay method Ikeda K et al . ( J Chromatogr B , 2008 ) perform Department Medicine , Faculty Medicine . Clinical data pathogen collection : 1 . Initial patient demographic data ( age , sex , weight , diagnosis , APACHE II score ) collect upon enrollment study . 2 . The Gram negative bacillus isolate sputum 12 patient collect MIC doripenem pathogen determine E test upon enrollment study . Duration study : Patients receive doripenem 3 day Pharmacokinetic pharmacodynamic analysis : Concentration doripenem plasma simulate Monte Carlo technique ( Computer model ) get PK/PD index ( 40 % T &gt; MIC ) report % PTA ( Probability Target Attainment ) % CFR ( Cumulative Faction Response ) Sample Size : Twelve patient VAP enrol study .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>Patients age ≥ 20 year Patients VAP Gram negative bacillus infection . The diagnosis VAP define new persistent infiltrate chest radiography associate least one following : purulent tracheal secretion ; temperature 38.3°C high ; leukocyte count high 10,000/mm3 Patients documented hypersensitivity doripenem carbapenems . Patients estimate creatinine clearance ≤ 50 ml/min Patients circulatory shock ( define systolic blood pressure &lt; 90 mmHg ) . Patients pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Infection</keyword>
	<keyword>Doripenem</keyword>
	<keyword>Ventilator-Associated Pneumonia</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>